All In Biotech

Drug Trial Radar · NCT04589845

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

920

Planned (sponsor's estimate)

Start

Jan 18, 2021

Primary completion

Sep 25, 2032

Study completion Sep 25, 2032

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug regimen tailored to their NGS assay results at screening. Participants will be assigned to the appropriate cohort based on their genetic alteration(s). Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.

Conditions

  • Solid Tumors

Interventions

  • EntrectinibDrug

    Adults and pediatric participants with a BSA ≥1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2) or 300 milligrams per square meter (mg/m\^2) (BSA=0.43-0.50 m\^2).

  • EntrectinibDrug

    Adults and pediatric participants with a BSA ≥ 1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2) or 300 mg/m\^2 (BSA=≤0.50 m\^2).

  • AlectinibDrug

    Alectinib will be administered orally BID with food at a dosage of 600 mg (four 150-mg capsules).

  • AtezolizumabDrug

    Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged ≥18 years, and 15 mg/kg (maximum 1200 mg) for participants aged \<18 years on Day 1 of each 21-day cycle.

  • IpatasertibDrug

    For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kg, 300 mg for participants ≥35 and \< 45 kg, 400 mg for those ≥ 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent.

  • Trastuzumab emtansineDrug

    Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age.

  • InavolisibDrug

    GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age.

  • BelvarafenibDrug

    Belvarafenib will be administered at a dose 400 mg, PO, BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.

  • PralsetinibDrug

    Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric participants ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days).

  • DivarasibDrug

    Divarasib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric participants. A treatment cycle consists of 3 weeks (21 days).

  • CamonsertibDrug

    Camonsertib will be self-administered by participants orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)Time frame: Approximately up to 12 years

Locations

112 sites in 23 countries. Site status is shown where the registry gives one.

  • Western Regional Medical Center at Cancer Treatment Centers of America

    Goodyear, Arizona

  • Kaiser Permanente Los Angeles

    Los Angeles, California

  • USC Norris Cancer Center

    Los Angeles, California

  • Hoag Memorial Hospital

    Newport Beach, California

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • University Cancer & Blood Center, LLC

    Athens, Georgia

  • St. Alphonsus

    Boise, Idaho

  • Midwestern Regional Med Center

    Zion, Illinois

  • Horizon Oncology Research, Inc.

    Lafayette, Indiana

  • Maryland Hematology & Oncology. P.A.

    Silver Spring, Maryland

  • Henry Ford Health System

    Detroit, Michigan

  • Metro-Minnesota Community Oncology Research Consortium

    Saint Louis Park, Minnesota

  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana

    Billings, Montana

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • University of New Mexico

    Albuquerque, New Mexico

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Montefiore Einstein Center for Cancer Care

    The Bronx, New York

  • Barrett Cancer Center

    Cincinnati, Ohio

  • Oncology Hematology Care Inc

    Cincinnati, Ohio

  • Consultants in Medical Oncology and Hematology

    Broomall, Pennsylvania

  • Alliance Cancer Specialists

    Horsham, Pennsylvania

  • Virginia Cancer Specialists - Leesburg

    Leesburg, Pennsylvania

  • Cancer Treatment Centers of America

    Philadelphia, Pennsylvania

  • The West Clinic

    Germantown, Tennessee

  • St. Jude Children'S Research Hospital

    Memphis, Tennessee

  • Texas Oncology - Central South

    Austin, Texas

  • Mary Crowley Medical Research Center

    Dallas, Texas

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • Texas Oncology- Northeast Texas

    Tyler, Texas

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington

  • Froedtert and The Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Kinghorn Cancer Centre

    Darlinghurst, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Royal Children's Hospital

    Parkville, Victoria, Australia

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • GHdC Site Les Viviers

    Charleroi, Belgium

  • UZ Antwerpen

    Edegem, Belgium

  • UZ Gent

    Ghent, Belgium

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.